The newly unveiled 2018 Canadian federal budget announced on Tuesday (February 27) offers cannabis investors a closer look into how the legal product will be taxed in the future.

Delivered by Finance Minister Bill Morneau, the document called “Equality + Growth, A Strong Middle Class,” presented all the spending done by the federal government to regulate the cannabis industry.


The budget indicates an excise duty framework is being proposed for the majority of cannabis products set to be available to consumers after the legalization of cannabis becomes official later this year.

Cannabis products with low amounts of tetrahydrocannabinol (THC) will not be taxed. Neither will pharmaceutical items derived from cannabis, as long as they have a Drug Identification Number and are only available to patients with a prescription.

Taxing for cannabis products will come down to two options: whichever is the highest applicable per product, either a $1 per gram standard or 10 percent of a product price.

The budget said:

“Under the framework, excise duties will be imposed on federally licensed producers at the higher of a flat rate applied on the quantity of cannabis contained in a final product, or a percentage of the sale price of the product sold by a federal licensee.

The proposed tax will kick off once sales of recreational cannabis become available in retail.

Patient advocacy group ‘outraged’ over budget proposals

A cannabis patients advocacy group, however, expressed disappointment on the Canadian budget. Canadians for Fair Access to Medical Marijuana (CFAMM) issued a statement saying they were “outraged” to find out the limits of the products that won’t be taxed.

CFAMM acknowledge the tax won’t affect products with low to no amounts of THC but said those products are actually a minority among the patient population and represent a small representation of use.

The government will exempt some products such as non-THC and low-THC medicine from the excise tax but those products represent a small minority of those used by patients. “It’s quite clear that Canadians understand that taxing medical cannabis is unfair and wrong,” Jonathan Zaid executive director of CFAMM stated.

“Exempting a small minority of patients does not address the affordability issue and implies some patients are more legitimate than others,” Zaid commented.

The actual breakdown of the tax will be split with 75 percent going to the Canadian provinces and territorial governments. The federal government will keep the remainder 25 percent. However, that sum will be capped annually at $100 million for the first two years after legalization.

All the extra money, in this case, will be sent back to the provinces as part of a special arrangement between the two levels of government. The arranged sums are expected to be delivered to municipalities and local communities due to, according to the budget, their role on “the front lines of legalization.”

Dan Kelly Dan Kelly president, CEO and chair Canadian Federation of Independent Business told Global News he is worried the government is asking for too much with this proposed tax.

“I think a smarter strategy would be to start with a very reasonable level of taxation to ensure that we get the business above ground before we start ratcheting it up,” he said.

A report on the entire budget prepared by business law firm Aird and Berlis indicated cannabis cultivators and manufacturers will now be required to get a license from Canada Revenue Agency (CRA) and “remit the excise duty, where applicable.”

Federal government will invest in cannabis research

The budget also included information on other areas related to the emerging cannabis industry the government plans to invest in. The Mental Health Commission will receive $10 million over five years to “assess the impact of cannabis use on the mental health of Canadians.”

Another $10 million, also over five years, will be given to the Canadian Centre on Substance Use and Addiction for research purposes.

It was also revealed how much will the government invest in the public education surrounding cannabis per year. Public education will get $18 million in 2018-2019, which then will go up to $16 million from the 2019-2020 cycle until the year 2023, resulting in a total $83 million campaign.

Investor Takeaway

Advocates of the industry have long argued for a complete removal of a tax on medical cannabis products. With the initial comments from CFAMM, it will be interesting to see how companies in the space react to their actions attempting to convince the government to remove the tax on medical products.

Observers of the cannabis space will also have to keep a close eye on the impact the tax on recreational products will have in deterring the illegal marijuana market.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

The new dispensary brings expanded access for patients along Florida’s Atlantic Coast

Trulieve Cannabis Corp. (CSE: TRUL)  (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 78th nationwide. The new 4,600 sq. ft. location marks the Company’s first in the city of Sebastian and second in Indian River county expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less